Journal article icon

Journal article

Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms

Abstract:

Dysregulation of epigenetic processes is increasingly understood to play a role in the pathogenesis of myeloproliferative neoplasms (MPNs). Ruxolitinib, a JAK/STAT inhibitor, has proved a useful addition to the therapeutic arsenal for these disorders, but has limited disease modifying activity. We determined the effect of JAK inhibition on the histone landscape of MPN cells in cell line models of MPNs and validated using samples from the MAJIC randomised clinical trial of ruxolitinib in polyc...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Role:
Author
ORCID:
0000-0003-2333-1374
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
RDM Clinical Laboratory Sciences
Role:
Author
ORCID:
0000-0001-8522-1002
More from this funder
Name:
Medical Research Council
Grant:
MR/L006340/1
MC_UU_00016/1
More from this funder
Name:
Kay Kendall Leukaemia Fund
Grant:
KKL811
Publisher:
MDPI
Journal:
Cancers More from this journal
Volume:
12
Issue:
9
Article number:
2669
Publication date:
2020-09-18
Acceptance date:
2020-09-15
DOI:
EISSN:
2072-6694
ISSN:
2072-6694
Pmid:
32962027
Language:
English
Keywords:
Pubs id:
1134835
Local pid:
pubs:1134835
Deposit date:
2021-01-21

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP